Abstract：
UNASSIGNED: The data on the use of dual biologics are scant, but a topic of current interest.
UNASSIGNED: In this report, the treatment regimen of a patient with two T helper 2 pathway-related comorbidities, severe asthma, and chronic spontaneous urticaria, was presented.
UNASSIGNED: Both urticaria and asthma symptoms of the patient could not be controlled entirely with monotherapy while both diseases could be controlled after omalizumab-mepolizumab dual treatment. No adverse events were observed after 6 months of dual biologics use.
UNASSIGNED: This report supports other publications in the literature involving the use of dual biologics and provides a summary of the literature.
UNASSIGNED: In this report, the treatment regimen of a patient with two T helper 2 pathway-related comorbidities, severe asthma, and chronic spontaneous urticaria, was presented.
UNASSIGNED: Both urticaria and asthma symptoms of the patient could not be controlled entirely with monotherapy while both diseases could be controlled after omalizumab-mepolizumab dual treatment. No adverse events were observed after 6 months of dual biologics use.
UNASSIGNED: This report supports other publications in the literature involving the use of dual biologics and provides a summary of the literature.
摘要：
简介：关于使用双重生物制剂的数据很少，而是当前感兴趣的话题。案例研究：在本报告中，对患有两种T辅助细胞2途径相关合并症的患者的治疗方案，严重哮喘,慢性自发性荨麻疹,被介绍了。结果：患者的荨麻疹和哮喘症状均不能通过单药治疗得到完全控制，而奥马珠单抗-美泊利单抗双重治疗后两种疾病均可得到控制。使用双重生物制剂6个月后未观察到不良事件。结论：本报告支持文献中涉及使用双重生物制剂的其他出版物，并提供了文献摘要。
